Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.030 -0.010 (-0.96%)

Official Closing Price Updated: 6:30 PM EST, Feb 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	97,339
Open	1.030
Bid (Size)	1.000 (100)
Ask (Size)	1.030 (500)
Prev. Close	1.040
Today's Range	0.9918 - 1.040
52wk Range	0.8500 - 2.230
Shares Outstanding	15,641,611
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 in MPox

February 12, 2026

Via Investor Brand Network

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

February 12, 2026

Via ACCESS Newswire

Performance

YTD	-14.9%	-14.9%
1 Month	-7.2%	-7.2%
3 Month	-18.3%	-18.3%
6 Month	-27.5%	-27.5%
1 Year	-18.3%	-18.3%

More News

NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX)

February 12, 2026

Via AB Newswire

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 as Measles Treatment

February 10, 2026

Via Investor Brand Network

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

February 10, 2026

Via ACCESS Newswire

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Mission Matters Podcast Interview With President Anil Diwan

February 02, 2026

Via Investor Brand Network

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

February 02, 2026

Via ACCESS Newswire

NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference

January 20, 2026

Via ACCESS Newswire

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Need for Broad-Spectrum Antivirals Amid Severe Influenza Season

January 13, 2026

Via Investor Brand Network

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

January 13, 2026

Via ACCESS Newswire

2 Small-Cap Biotechs That Could Reward Patient Investors ↗

December 12, 2025

Via MarketBeat

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Signs Master Services Agreement With Only Orphans Cote for NV-387 Orphan Drug Strategy

December 01, 2025

Via Investor Brand Network

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

December 01, 2025

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Files Quarterly Report Highlighting Broad-Spectrum Antiviral Candidate NV-387

November 17, 2025

Via Investor Brand Network

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

November 17, 2025

Via ACCESS Newswire

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

November 14, 2025

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Closes $6 Million Registered Direct Offering With Concurrent Private Placement of Warrants

November 13, 2025

Via Investor Brand Network

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

November 12, 2025

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces $6 Million Registered Direct Offering with Concurrent Private Placement of Warrants

November 11, 2025

Via Investor Brand Network

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

November 11, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 10, 2025

Via Benzinga

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Regulatory Approval to Begin Phase II Trial of NV-387 for Treatment of MPox in the DRC

November 10, 2025

Via Investor Brand Network

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

November 10, 2025

Via ACCESS Newswire

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces Date and Location of 2025 Annual Shareholders Meeting

November 05, 2025

Via Investor Brand Network

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

November 05, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is NanoViricides, Inc. Common Stock publicly traded?

Yes, NanoViricides, Inc. Common Stock is publicly traded.

What exchange does NanoViricides, Inc. Common Stock trade on?

NanoViricides, Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for NanoViricides, Inc. Common Stock?

The ticker symbol for NanoViricides, Inc. Common Stock is NNVC on the New York Stock Exchange

What is the current price of NanoViricides, Inc. Common Stock?

The current price of NanoViricides, Inc. Common Stock is 1.030

When was NanoViricides, Inc. Common Stock last traded?

The last trade of NanoViricides, Inc. Common Stock was at 02/25/26 06:30 PM ET

What is the market capitalization of NanoViricides, Inc. Common Stock?

The market capitalization of NanoViricides, Inc. Common Stock is 16.11M

How many shares of NanoViricides, Inc. Common Stock are outstanding?

NanoViricides, Inc. Common Stock has 16M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.